188 related articles for article (PubMed ID: 24869613)
21. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles.
Minoo P; Zlobec I; Peterson M; Terracciano L; Lugli A
Int J Oncol; 2010 Sep; 37(3):707-18. PubMed ID: 20664940
[TBL] [Abstract][Full Text] [Related]
22. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas.
Li M; Li JY; Zhao AL; Gu J
Oncology; 2007; 73(1-2):52-7. PubMed ID: 18334831
[TBL] [Abstract][Full Text] [Related]
23. Semi-quantitative procedure for telomeric repeat amplification protocol (TRAP) assay in colorectal carcinomas.
Fujita M; Tomita S; Fukui H; Ueda Y; Fujimori T
J Exp Clin Cancer Res; 1999 Mar; 18(1):119-24. PubMed ID: 10374691
[TBL] [Abstract][Full Text] [Related]
24. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer.
Sanchez JA; Dejulius KL; Bronner M; Church JM; Kalady MF
Inflamm Bowel Dis; 2011 Sep; 17(9):1966-70. PubMed ID: 21618350
[TBL] [Abstract][Full Text] [Related]
25. Genetic mechanisms in interval colon cancers.
Richter JM; Pino MS; Austin TR; Campbell E; Szymonifka J; Russo AL; Hong TS; Borger D; Iafrate AJ; Chung DC
Dig Dis Sci; 2014 Sep; 59(9):2255-63. PubMed ID: 24705641
[TBL] [Abstract][Full Text] [Related]
26. Suppressor of Ty homolog-5, a novel tumor-specific human telomerase reverse transcriptase promoter-binding protein and activator in colon cancer cells.
Chen R; Zhu J; Dong Y; He C; Hu X
Oncotarget; 2015 Oct; 6(32):32841-55. PubMed ID: 26418880
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical detection of telomerase reverse transcriptase in colorectal adenocarcinoma and benign colonic mucosa.
Wei R; Younes M
Hum Pathol; 2002 Jul; 33(7):693-6. PubMed ID: 12196919
[TBL] [Abstract][Full Text] [Related]
28. The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer.
Hong SP; Min BS; Kim TI; Cheon JH; Kim NK; Kim H; Kim WH
Eur J Cancer; 2012 May; 48(8):1235-43. PubMed ID: 22071131
[TBL] [Abstract][Full Text] [Related]
29. hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features.
Lam AK; Ong K; Ho YH
Int J Colorectal Dis; 2008 Jun; 23(6):587-94. PubMed ID: 18322660
[TBL] [Abstract][Full Text] [Related]
30. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer.
Malecka-Panas E; Kordek R; Biernat W; Tureaud J; Liberski PP; Majumdar AP
Hepatogastroenterology; 1997; 44(14):435-40. PubMed ID: 9164515
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2.
Buglioni S; D'Agnano I; Cosimelli M; Vasselli S; D'Angelo C; Tedesco M; Zupi G; Mottolese M
Int J Cancer; 1999 Dec; 84(6):545-52. PubMed ID: 10567896
[TBL] [Abstract][Full Text] [Related]
32. Predictive utility of cyclo-oxygenase-2 expression by colon and rectal cancer.
Lobo Prabhu KC; Vu L; Chan SK; Phang T; Gown A; Jones SJ; Wiseman SM
Am J Surg; 2014 May; 207(5):712-6. PubMed ID: 24791632
[TBL] [Abstract][Full Text] [Related]
33. Analysis of clinicopathological features and prognosis of 1315 cases in colorectal cancer located at different anatomical subsites.
Feng Z; Shi X; Zhang Q; Zhang X; Li X; Chen Z; Liu D; Sun B; Zuo Y; Ren S
Pathol Res Pract; 2019 Oct; 215(10):152560. PubMed ID: 31375274
[TBL] [Abstract][Full Text] [Related]
34. Ionizing radiation, inflammation, and their interactions in colon carcinogenesis in Mlh1-deficient mice.
Morioka T; Miyoshi-Imamura T; Blyth BJ; Kaminishi M; Kokubo T; Nishimura M; Kito S; Tokairin Y; Tani S; Murakami-Murofushi K; Yoshimi N; Shimada Y; Kakinuma S
Cancer Sci; 2015 Mar; 106(3):217-26. PubMed ID: 25529563
[TBL] [Abstract][Full Text] [Related]
35. Microsatellite instability and survival in rectal cancer.
Samowitz WS; Curtin K; Wolff RK; Tripp SR; Caan BJ; Slattery ML
Cancer Causes Control; 2009 Nov; 20(9):1763-8. PubMed ID: 19669908
[TBL] [Abstract][Full Text] [Related]
36. The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer.
Hilska M; Collan YU; O Laine VJ; Kössi J; Hirsimäki P; Laato M; Roberts PJ
Dis Colon Rectum; 2005 Dec; 48(12):2197-208. PubMed ID: 16400510
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic features and prognostic analysis of MSI-high colon cancer.
Lin CC; Lai YL; Lin TC; Chen WS; Jiang JK; Yang SH; Wang HS; Lan YT; Liang WY; Hsu HM; Lin JK; Chang SC
Int J Colorectal Dis; 2012 Mar; 27(3):277-86. PubMed ID: 22076610
[TBL] [Abstract][Full Text] [Related]
38. Change in telomerase activity during human colorectal carcinogenesis.
Yoshida R; Kiyozuka Y; Ichiyoshi H; Senzaki H; Takada H; Hioki K; Tsubura A
Anticancer Res; 1999; 19(3B):2167-72. PubMed ID: 10472326
[TBL] [Abstract][Full Text] [Related]
39. Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas.
Diez M; Medrano M; Mugüerza JM; Ramos P; Hernandez P; Villeta R; Martín A; Noguerales F; Ruiz A; Granell J
Anticancer Res; 2000; 20(5C):3907-12. PubMed ID: 11268475
[TBL] [Abstract][Full Text] [Related]
40. Verification of a new clinicopathologic staging system for colorectal adenocarcinoma.
Michelassi F; Ayala JJ; Balestracci T; Goldberg R; Chappell R; Block GE
Ann Surg; 1991 Jul; 214(1):11-8. PubMed ID: 2064465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
